ACV tripeptide
Source ACV tripeptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Delta‑(L‑α‑aminoadipyl)‑L‑cysteinyl‑D‑valine (ACV) is a non‑ribosomal tripeptide intermediate produced by fungi and some bacteria during the early steps of β‑lactam antibiotic biosynthesis. It is the first dedicated precursor that is converted into isopenicillin N and subsequently into penicillins and cephalosporins, making it central to industrial production of these drugs.
Mechanism of Action
ACV is assembled by the ACV synthetase (ACVS), a large modular non‑ribosomal peptide synthetase. The enzyme contains three repeat modules, each with adenylation (A), condensation (C) and thiolation (T) domains that activate L‑α‑aminoadipic acid, L‑cysteine and L‑valine, respectively. The third module also carries an epimerization (E) domain that converts L‑valine to D‑valine while the peptide remains enzyme‑bound. A C‑terminal thioesterase domain releases the completed ACV tripeptide in the correct L‑L‑D configuration, ready for cyclization into isopenicillin N.
What the Research Shows
Early work identified ACV in Penicillium chrysogenum and Acremonium chrysogenum and cloned the 11 kb pchAB gene encoding its synthetase. Molecular studies in Aspergillus nidulans revealed a 3,770‑aa enzyme with three homologous regions resembling adenylate‑forming enzymes and multienzyme peptide synthetases. Comparative genomics highlighted conserved epimerization motifs and a thioesterase domain. Recent investigations showed that the vacuolar membrane transporter PenV supplies precursor amino acids to the membrane‑anchored ACVS, and that intracellular glutathione can inhibit the β‑lactam pathway. A 2017 review summarized the enzyme’s discovery, partial characterization, and ongoing gaps in mechanistic understanding.
Reported Benefits
Understanding ACV biosynthesis enables targeted engineering of penicillin‑producing strains, potentially increasing yields and allowing the creation of novel β‑lactam structures. Manipulating the ACV synthetase or its associated transporters can improve industrial fermentation efficiency and provide a platform for generating new antibiotics through synthetic biology approaches.
Limitations of the Evidence
Current knowledge of ACVS is incomplete: the enzyme’s large size and instability hinder detailed mechanistic and structural studies, and the exact sequence of catalytic events remains uncertain. Regulatory networks governing ACV production, such as the influence of glutathione and vacuolar transport, are only partially elucidated. No clinical data exist because ACV itself is not used as a therapeutic agent.
Safety Considerations
ACV has not been evaluated for human safety and is not an approved drug. It is a microbial metabolite that may be cytotoxic at high concentrations, but no adverse‑effect data are reported in the literature. Consequently, any handling should follow standard biosafety procedures for fungal or bacterial cultures, and it should not be administered to patients.
How It Is Administered
ACV is not formulated for clinical administration. It is generated intracellularly during fungal or bacterial fermentation and remains bound to the ACV synthetase until release as a biosynthetic intermediate. Research use typically involves recombinant expression or purification from microbial cultures.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateMartin JF2000-01-01T00:00:00.000000Z
- Journal ArticleModerateTurner G1992-01-01T00:00:00.000000Z
- Journal ArticleLowMacCabe AP, et al.1991-01-01T00:00:00.000000Z
- Journal ArticleLowFernández-Aguado M, et al.2013-01-01T00:00:00.000000Z
- Journal ArticleLowPócsi I, et al.2001-01-01T00:00:00.000000Z
- Journal ArticleModerateTahlan K, Moore MA, Jensen SE2017-01-01T00:00:00.000000Z
Frequently Asked Questions
What is the ACV tripeptide?
ACV (δ‑(L‑α‑aminoadipyl)‑L‑cysteinyl‑D‑valine) is a three‑amino‑acid peptide made by non‑ribosomal synthesis in fungi and some bacteria. It is the first dedicated precursor in the pathway that creates β‑lactam antibiotics such as penicillins.
Is ACV used as a medicine?
No. ACV is an intracellular biosynthetic intermediate, not a marketed drug. Its importance lies in enabling the production of penicillin‑type antibiotics, not as a therapeutic itself.
How is ACV produced in the laboratory?
Microorganisms that naturally make β‑lactams, such as Penicillium chrysogenum, are cultured in fermentation broth. The ACV synthetase enzyme assembles the tripeptide from L‑α‑aminoadipic acid, L‑cysteine and D‑valine within the cell.
Can ACV be engineered to create new antibiotics?
Research suggests that modifying the ACV synthetase or its supplying transporters could alter the tripeptide’s composition, providing a route to novel β‑lactam structures, though the enzyme’s complexity makes such engineering challenging.
Are there any known safety concerns with ACV?
There are no published safety studies in humans. As a microbial metabolite, it is handled under standard laboratory biosafety conditions, and it is not intended for ingestion or injection.